⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19545982 | 0.82 | — | — | |
| SCHEMBL16205327 | 0.79 | — | — | |
| SCHEMBL27271966 | 0.79 | — | — | |
| SCHEMBL18727111 | 0.77 | LMNA (0.33) | — | |
| SCHEMBL14417702 | 0.77 | TSHR (0.32) | — | |
| SCHEMBL178564 | 0.75 | — | — | |
| SCHEMBL5210963 | 0.75 | — | — | |
| SCHEMBL14632256 | 0.75 | PRMT3 (0.33) | — | |
| SCHEMBL6286736 | 0.74 | HSD17B10 (0.33) | — | |
| SCHEMBL19102236 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250339569-A1 | CARBONIC ANHYDRASE IX LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2025-11-06 | — | — | US | disclosed |
| US-20250296971-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2025-09-25 | — | — | US | disclosed |
| EP-4448544-A2 | CARBONIC ANHYDRASE IX LIGANDS | 3B Pharmaceuticals GmbH (DE) | 2024-10-23 | — | — | EP | disclosed |
| CN-118632858-A | Gastric inhibitory peptide receptor ligands | 3B制药有限公司 | 2024-09-10 | — | — | CN | disclosed |
| EP-4423110-A2 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B Pharmaceuticals GmbH (DE) | 2024-09-04 | — | — | EP | disclosed |
| WO-2023111350-A2 | CARBONIC ANHYDRASE IX LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023072971-A2 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2023-05-04 | — | — | WO | disclosed |
| EP-4170347-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B Pharmaceuticals GmbH (DE) | 2023-04-26 | — | — | EP | disclosed |
| US-20170267698-A1 | NITROGEN-CONTAINING MACROCYCLIC CONJUGATES AS RADIOPHARMACEUTICALS | Clarity Pharmaceuticals Ltd (AU) | 2017-09-21 | — | — | US | disclosed |
| US-9701694-B2 | Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals | THE UNIVERSITY OF MELBOURNE (AU) | 2017-07-11 | — | — | US | disclosed |
| US-20160354497-A1 | CAGE AMINE LIGANDS FOR METALLO-RADIOPHARMACEUTICALS | THE UNIVERSITY OF MELBOURNE (AU) | 2016-12-08 | — | — | US | disclosed |
| US-9364570-B2 | Functionalisation of cage amine ligands for metallo-radiopharmaceuticals | THE UNIVERSITY OF MELBOURNE (AU) | 2016-06-14 | — | — | US | disclosed |
| US-20150051392-A1 | FUNCTIONALISATION OF CAGE AMINE LIGANDS FOR METALLO-RADIOPHARMACEUTICALS | THE UNIVERSITY OF MELBOURNE (AU) | 2015-02-19 | — | — | US | disclosed |
| EP-2016046-B1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2012-07-11 | — | — | EP | disclosed |
| US-20110293517-A1 | Nitrogen-Containing Macrocyclic Conjugates As Radiopharmaceuticals | THE UNIVERSITY OF MELBOURNE (AU) | 2011-12-01 | — | — | US | disclosed |
| US-8066974-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2011-11-29 | — | — | US | disclosed |
| US-20090136425-A1 | CONTRAST AGENTS | WYNN DUNCAN | 2009-05-28 | — | — | US | disclosed |
| EP-2016046-A1 | CONTRAST AGENTS | GE Healthcare AS (NO) | 2009-01-21 | — | — | EP | disclosed |
| WO-2007133088-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2007-11-22 | — | — | WO | disclosed |
| US-20060189774-A1 | Modifiable polyunsaturated polymers and processes for their preparation | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH | 2006-08-24 | — | — | US | disclosed |